Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTTYMPS6)

• DOT Name: Large ribosomal subunit protein uL22 (RPL17)
• Synonyms: 60S ribosomal protein L17; 60S ribosomal protein L23; PD-1
• Gene Name: RPL17
• Related Disease:
  Adenocarcinoma
  Adult T-cell leukemia/lymphoma
  Advanced cancer
  Ankylosing spondylitis
  Autoimmune disease
  B-cell neoplasm
  Brain neoplasm
  Breast cancer
  Breast carcinoma
  Carcinoma of esophagus
  Clear cell renal carcinoma
  Colorectal carcinoma
  Cytomegalovirus infection
  Depression
  Endometrial cancer
  Endometrial carcinoma
  Epithelial ovarian cancer
  Esophageal cancer
  Graves disease
  Hepatitis C virus infection
  HIV infectious disease
  Immunodeficiency
  Lung adenocarcinoma
  Lung cancer
  Lung carcinoma
  Lupus
  Myocardial ischemia
  Neoplasm of esophagus
  Nephropathy
  Plasma cell myeloma
  Pulmonary fibrosis
  Renal cell carcinoma
  Rheumatoid arthritis
  Systemic lupus erythematosus
  T-cell lymphoma
  Type-1 diabetes
  Head-neck squamous cell carcinoma
  Immune system disorder
  Kidney cancer
  Small-cell lung cancer
  Adult glioblastoma
  Glioblastoma multiforme
  Pancreatic ductal carcinoma
  Hepatocellular carcinoma
  Malignant soft tissue neoplasm
  Melanoma
  Neoplasm
  Sarcoma
• UniProt ID: RL17_HUMAN
• PDB ID: 4UG0 ; 4V6X ; 5A8L ; 5AJ0 ; 5LKS ; 5T2C ; 6IP5 ; 6IP6 ; 6IP8 ; 6LQM ; 6LSR ; 6LSS ; 6LU8 ; 6OLE ; 6OLF ; 6OLG ; 6OLI ; 6OLZ ; 6OM0 ; 6OM7 ; 6QZP ; 6W6L ; 6XA1 ; 6Y0G ; 6Y2L ; 6Y57 ; 6Y6X ; 6Z6L ; 6Z6M ; 6Z6N ; 6ZM7 ; 6ZME ; 6ZMI ; 6ZMO ; 7BHP ; 7F5S ; 7OW7 ; 7QVP ; 7XNX ; 7XNY ; 8A3D ; 8FKP ; 8FKQ ; 8FKR ; 8FKS ; 8FKT ; 8FKU ; 8FKV ; 8FKW ; 8FKX ; 8FKY ; 8FKZ ; 8FL2 ; 8FL3 ; 8FL4 ; 8FL6 ; 8FL7 ; 8FL9 ; 8FLA ; 8FLB ; 8FLC ; 8FLD ; 8FLE ; 8FLF ; 8G5Y ; 8G5Z ; 8G60 ; 8G61 ; 8G6J ; 8GLP ; 8IDT ; 8IDY ; 8IE3 ; 8INE ; 8INF ; 8INK ; 8IPD ; 8IPX ; 8IPY ; 8IR1 ; 8IR3 ; 8JDJ ; 8JDK ; 8JDL ; 8JDM
• Pfam ID: PF00237
• Sequence:
  MVRYSLDPENPTKSCKSRGSNLRVHFKNTRETAQAIKGMHIRKATKYLKDVTLQKQCVPF
  RRYNGGVGRCAQAKQWGWTQGRWPKKSAEFLLHMLKNAESNAELKGLDVDSLVIEHIQVN
  KAPKMRRRTYRAHGRINPYMSSPCHIEMILTEKEQIVPKPEEEVAQKKKISQKKLKKQKL
  MARE
• Function: Component of the large ribosomal subunit. The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell.
• Tissue Specificity: Expressed in pancreas, lung, colon, cystic duct, gall bladder, kidney and liver. Expressed at high levels in the well differentiated pancreatic tumor cell lines HPAF, COLO 357 and Capan-1, the moderately differentiated pancreatic tumor cell lines T3M-4, AsPc-1 and BxPc-3, the poorly differentiated pancreatic tumor cell line MIA PaCa-2, and the pancreatic tumor cell lines of undefined differentiation status such as SW979. Expressed at lower levels in the poorly differentiated pancreatic tumor cell lines HCG-25 and PANC-1.
• KEGG Pathway:
  Ribosome (hsa03010)
  Coro.virus disease - COVID-19 (hsa05171)
• Reactome Pathway:
  Peptide chain elongation (R-HSA-156902)
  SRP-dependent cotranslational protein targeting to membrane (R-HSA-1799339)
  Viral mRNA Translation (R-HSA-192823)
  Selenocysteine synthesis (R-HSA-2408557)
  Major pathway of rRNA processing in the nucleolus and cytosol (R-HSA-6791226)
  Formation of a pool of free 40S subunits (R-HSA-72689)
  GTP hydrolysis and joining of the 60S ribosomal subunit (R-HSA-72706)
  Eukaryotic Translation Termination (R-HSA-72764)
  Regulation of expression of SLITs and ROBOs (R-HSA-9010553)
  Response of EIF2AK4 (GCN2) to amino acid deficiency (R-HSA-9633012)
  Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) (R-HSA-975956)
  Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) (R-HSA-975957)
  L13a-mediated translational silencing of Ceruloplasmin expression (R-HSA-156827)

Molecular Interaction Atlas (MIA) of This DOT

48 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Adenocarcinoma	DIS3IHTY	Definitive	Altered Expression	[1]
Adult T-cell leukemia/lymphoma	DIS882XU	Strong	Biomarker	[2]
Advanced cancer	DISAT1Z9	Strong	Biomarker	[3]
Ankylosing spondylitis	DISRC6IR	Strong	Genetic Variation	[4]
Autoimmune disease	DISORMTM	Strong	Genetic Variation	[5]
B-cell neoplasm	DISVY326	Strong	Biomarker	[6]
Brain neoplasm	DISY3EKS	Strong	Genetic Variation	[7]
Breast cancer	DIS7DPX1	Strong	Altered Expression	[8]
Breast carcinoma	DIS2UE88	Strong	Altered Expression	[8]
Carcinoma of esophagus	DISS6G4D	Strong	Biomarker	[9]
Clear cell renal carcinoma	DISBXRFJ	Strong	Altered Expression	[10]
Colorectal carcinoma	DIS5PYL0	Strong	Biomarker	[11]
Cytomegalovirus infection	DISCEMGC	Strong	Genetic Variation	[12]
Depression	DIS3XJ69	Strong	Biomarker	[13]
Endometrial cancer	DISW0LMR	Strong	Biomarker	[14]
Endometrial carcinoma	DISXR5CY	Strong	Biomarker	[14]
Epithelial ovarian cancer	DIS56MH2	Strong	Genetic Variation	[15]
Esophageal cancer	DISGB2VN	Strong	Biomarker	[9]
Graves disease	DISU4KOQ	Strong	Biomarker	[16]
Hepatitis C virus infection	DISQ0M8R	Strong	Biomarker	[17]
HIV infectious disease	DISO97HC	Strong	Biomarker	[18]
Immunodeficiency	DIS093I0	Strong	Altered Expression	[19]
Lung adenocarcinoma	DISD51WR	Strong	Biomarker	[20]
Lung cancer	DISCM4YA	Strong	Biomarker	[21]
Lung carcinoma	DISTR26C	Strong	Biomarker	[21]
Lupus	DISOKJWA	Strong	Genetic Variation	[22]
Myocardial ischemia	DISFTVXF	Strong	Biomarker	[23]
Neoplasm of esophagus	DISOLKAQ	Strong	Biomarker	[9]
Nephropathy	DISXWP4P	Strong	Genetic Variation	[22]
Plasma cell myeloma	DIS0DFZ0	Strong	Biomarker	[24]
Pulmonary fibrosis	DISQKVLA	Strong	Altered Expression	[25]
Renal cell carcinoma	DISQZ2X8	Strong	Altered Expression	[10]
Rheumatoid arthritis	DISTSB4J	Strong	Biomarker	[26]
Systemic lupus erythematosus	DISI1SZ7	Strong	Genetic Variation	[27]
T-cell lymphoma	DISSXRTQ	Strong	Biomarker	[28]
Type-1 diabetes	DIS7HLUB	Strong	Genetic Variation	[29]
Head-neck squamous cell carcinoma	DISF7P24	moderate	Biomarker	[30]
Immune system disorder	DISAEGPH	moderate	Biomarker	[31]
Kidney cancer	DISBIPKM	moderate	Biomarker	[32]
Small-cell lung cancer	DISK3LZD	moderate	Biomarker	[33]
Adult glioblastoma	DISVP4LU	Disputed	Altered Expression	[34]
Glioblastoma multiforme	DISK8246	Disputed	Altered Expression	[34]
Pancreatic ductal carcinoma	DIS26F9Q	Disputed	Altered Expression	[35]
Hepatocellular carcinoma	DIS0J828	Limited	Biomarker	[36]
Malignant soft tissue neoplasm	DISTC6NO	Limited	Biomarker	[37]
Melanoma	DIS1RRCY	Limited	Biomarker	[38]
Neoplasm	DISZKGEW	Limited	Biomarker	[39]
Sarcoma	DISZDG3U	Limited	Biomarker	[37]

11 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Doxorubicin	DMVP5YE	Approved	Doxorubicin decreases the expression of Large ribosomal subunit protein uL22 (RPL17).	[40]
Cupric Sulfate	DMP0NFQ	Approved	Cupric Sulfate decreases the expression of Large ribosomal subunit protein uL22 (RPL17).	[41]
Ivermectin	DMDBX5F	Approved	Ivermectin decreases the expression of Large ribosomal subunit protein uL22 (RPL17).	[42]
Arsenic trioxide	DM61TA4	Approved	Arsenic trioxide decreases the expression of Large ribosomal subunit protein uL22 (RPL17).	[43]
Marinol	DM70IK5	Approved	Marinol increases the expression of Large ribosomal subunit protein uL22 (RPL17).	[44]
Demecolcine	DMCZQGK	Approved	Demecolcine decreases the expression of Large ribosomal subunit protein uL22 (RPL17).	[45]
Epigallocatechin gallate	DMCGWBJ	Phase 3	Epigallocatechin gallate increases the expression of Large ribosomal subunit protein uL22 (RPL17).	[46]
Bisphenol A	DM2ZLD7	Investigative	Bisphenol A decreases the expression of Large ribosomal subunit protein uL22 (RPL17).	[49]
Formaldehyde	DM7Q6M0	Investigative	Formaldehyde decreases the expression of Large ribosomal subunit protein uL22 (RPL17).	[50]
chloropicrin	DMSGBQA	Investigative	chloropicrin decreases the expression of Large ribosomal subunit protein uL22 (RPL17).	[51]
Deguelin	DMXT7WG	Investigative	Deguelin increases the expression of Large ribosomal subunit protein uL22 (RPL17).	[52]

2 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
TAK-243	DM4GKV2	Phase 1	TAK-243 increases the sumoylation of Large ribosomal subunit protein uL22 (RPL17).	[47]
PMID28870136-Compound-52	DMFDERP	Patented	PMID28870136-Compound-52 decreases the phosphorylation of Large ribosomal subunit protein uL22 (RPL17).	[48]

References

• [1] Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma.Cancer Immunol Res. 2015 Oct;3(10):1123-1129. doi: 10.1158/2326-6066.CIR-15-0046. Epub 2015 Jun 16.
• [2] Lack of recall response to Tax in ATL and HAM/TSP patients but not in asymptomatic carriers of human T-cell leukemia virus type 1.J Clin Immunol. 2013 Oct;33(7):1223-39. doi: 10.1007/s10875-013-9918-x. Epub 2013 Jul 26.
• [3] PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges.Biomed Pharmacother. 2020 Jan;121:109625. doi: 10.1016/j.biopha.2019.109625. Epub 2019 Nov 13.
• [4] The associations between PD-1, CTLA-4 gene polymorphisms and susceptibility to ankylosing spondylitis: a meta-analysis and systemic review.Rheumatol Int. 2016 Jan;36(1):33-44. doi: 10.1007/s00296-015-3327-9. Epub 2015 Aug 1.
• [5] PD-1/PD-L and autoimmunity: A growing relationship.Cell Immunol. 2016 Dec;310:27-41. doi: 10.1016/j.cellimm.2016.09.009. Epub 2016 Sep 15.
• [6] Therapeutic Efficacy of 4-1BB Costimulation Is Abrogated by PD-1 Blockade in a Model of Spontaneous B-cell Lymphoma.Cancer Immunol Res. 2017 Mar;5(3):191-197. doi: 10.1158/2326-6066.CIR-16-0249. Epub 2017 Jan 23.
• [7] Association of PD-1.5 C/T, but Not PD-1.3 G/A, with Malignant and Benign Brain Tumors in Iranian Patients.Immunol Invest. 2017 Jul;46(5):469-480. doi: 10.1080/08820139.2017.1296858. Epub 2017 May 23.
• [8] Co-expression network analysis of gene expression profiles of HER2(+) breast cancer-associated brain metastasis.Oncol Lett. 2018 Dec;16(6):7008-7019. doi: 10.3892/ol.2018.9562. Epub 2018 Oct 10.
• [9] PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer.Cell Physiol Biochem. 2017;42(6):2267-2280. doi: 10.1159/000480000. Epub 2017 Aug 17.
• [10] Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma.Ann Diagn Pathol. 2017 Aug;29:17-22. doi: 10.1016/j.anndiagpath.2017.04.007. Epub 2017 Apr 24.
• [11] Integrating Immunotherapy Into Colorectal Cancer Care.Oncology (Williston Park). 2018 Oct 15;32(10):494-8.
• [12] Association between a polymorphism in the human programmed death-1 (PD-1) gene and cytomegalovirus infection after kidney transplantation.J Med Genet. 2010 Jan;47(1):54-8. doi: 10.1136/jmg.2009.068841. Epub 2009 Jul 5.
• [13] Integrated profiling of phenotype and blood transcriptome for stress vulnerability and depression.J Psychiatr Res. 2018 Sep;104:202-210. doi: 10.1016/j.jpsychires.2018.08.010. Epub 2018 Aug 6.
• [14] Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.JAMA Oncol. 2015 Dec;1(9):1319-23. doi: 10.1001/jamaoncol.2015.2151.
• [15] The effect of polymorphisms in PD-1 gene on the risk of epithelial ovarian cancer and patients' outcomes.Gynecol Oncol. 2017 Jan;144(1):140-145. doi: 10.1016/j.ygyno.2016.11.010. Epub 2016 Nov 9.
• [16] Frequencies of PD-1- positive T CD3+CD4+, T CD3+CD8+ and BCD19+ lymphocytes in female patients with Graves' disease and healthy controls- preliminary study.Mol Cell Endocrinol. 2017 Jun 15;448:28-33. doi: 10.1016/j.mce.2017.03.006. Epub 2017 Mar 8.
• [17] A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection.PLoS One. 2013 May 22;8(5):e63818. doi: 10.1371/journal.pone.0063818. Print 2013.
• [18] Cutting edge: Prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells.J Immunol. 2013 Jul 15;191(2):540-4. doi: 10.4049/jimmunol.1203161. Epub 2013 Jun 14.
• [19] Feline programmed death and its ligand: characterization and changes with feline immunodeficiency virus infection.Vet Immunol Immunopathol. 2010 Mar 15;134(1-2):107-14. doi: 10.1016/j.vetimm.2009.10.019. Epub 2009 Oct 14.
• [20] Association of PD-1 polymorphisms with the risk and prognosis of lung adenocarcinoma in the northeastern Chinese Han population.BMC Med Genet. 2019 Nov 12;20(1):177. doi: 10.1186/s12881-019-0914-8.
• [21] The changing face of cancer treatments.BMJ Case Rep. 2018 Sep 1;2018:bcr2018224784. doi: 10.1136/bcr-2018-224784.
• [22] A putative regulatory polymorphism in PD-1 is associated with nephropathy in a population-based cohort of systemic lupus erythematosus patients.Lupus. 2004;13(7):510-6. doi: 10.1191/0961203303lu1052oa.
• [23] Cardioplegia prevents ischemia-induced transcriptional alterations of cytoprotective genes in rat hearts: a DNA microarray study.J Thorac Cardiovasc Surg. 2005 Oct;130(4):1151. doi: 10.1016/j.jtcvs.2005.06.027.
• [24] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.Blood. 2017 Sep 7;130(10):1189-1197. doi: 10.1182/blood-2017-03-775122. Epub 2017 May 1.
• [25] Characterization of CD28(null) T cells in idiopathic pulmonary fibrosis.Mucosal Immunol. 2019 Jan;12(1):212-222. doi: 10.1038/s41385-018-0082-8. Epub 2018 Oct 12.
• [26] Extracellular Vesicles Transfer the Receptor Programmed Death-1 in Rheumatoid Arthritis.Front Immunol. 2017 Jul 24;8:851. doi: 10.3389/fimmu.2017.00851. eCollection 2017.
• [27] Effects of the programmed cell death 1 (PDCD1) polymorphisms in susceptibility to systemic lupus erythematosus.Int J Immunogenet. 2020 Feb;47(1):57-64. doi: 10.1111/iji.12456. Epub 2019 Sep 29.
• [28] PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis.Nature. 2017 Dec 7;552(7683):121-125. doi: 10.1038/nature24649. Epub 2017 Nov 15.
• [29] PD-1 gene haplotype is associated with the development of type 1 diabetes mellitus in Japanese children.Hum Genet. 2007 Apr;121(2):223-32. doi: 10.1007/s00439-006-0309-8. Epub 2007 Jan 3.
• [30] Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer.Clin Cancer Res. 2020 Jan 1;26(1):290-300. doi: 10.1158/1078-0432.CCR-19-1351. Epub 2019 Sep 27.
• [31] Frontline Science: Anti-PD-L1 protects against infection with common bacterial pathogens after burn injury.J Leukoc Biol. 2018 Jan;103(1):23-33. doi: 10.1002/JLB.5HI0917-360R. Epub 2017 Dec 21.
• [32] A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy.Mol Cancer Ther. 2019 Jun;18(6):1081-1091. doi: 10.1158/1535-7163.MCT-18-0737. Epub 2019 Apr 23.
• [33] Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer.Cancer Res. 2018 Aug 1;78(15):4270-4281. doi: 10.1158/0008-5472.CAN-17-2176. Epub 2018 May 18.
• [34] PD-L1/PD-1 Axis in Glioblastoma Multiforme.Int J Mol Sci. 2019 Oct 28;20(21):5347. doi: 10.3390/ijms20215347.
• [35] IFN- down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer.BMC Cancer. 2019 Nov 6;19(1):1053. doi: 10.1186/s12885-019-6145-8.
• [36] Programmed Death Receptor 1 (PD1) Knockout and Human Telomerase Reverse Transcriptase (hTERT) Transduction Can Enhance Persistence and Antitumor Efficacy of Cytokine-Induced Killer Cells Against Hepatocellular Carcinoma.Med Sci Monit. 2018 Jul 3;24:4573-4582. doi: 10.12659/MSM.910903.
• [37] Emerging Targeted and Immune-Based Therapies in Sarcoma.J Clin Oncol. 2018 Jan 10;36(2):125-135. doi: 10.1200/JCO.2017.75.1610. Epub 2017 Dec 8.
• [38] Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism.Am J Emerg Med. 2017 Jul;35(7):1039.e5-1039.e7. doi: 10.1016/j.ajem.2017.02.048. Epub 2017 Feb 27.
• [39] Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways.Cell Death Dis. 2019 Mar 18;10(4):261. doi: 10.1038/s41419-019-1497-1.
• [40] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [41] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [42] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [43] Gene expression profile changes in NB4 cells induced by arsenic trioxide. Acta Pharmacol Sin. 2003 Jul;24(7):646-50.
• [44] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [45] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [46] Comparative proteomics reveals concordant and discordant biochemical effects of caffeine versus epigallocatechin-3-gallate in human endothelial cells. Toxicol Appl Pharmacol. 2019 Sep 1;378:114621. doi: 10.1016/j.taap.2019.114621. Epub 2019 Jun 10.
• [47] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [48] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [49] Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.
• [50] Gene expression changes in primary human nasal epithelial cells exposed to formaldehyde in vitro. Toxicol Lett. 2010 Oct 5;198(2):289-95.
• [51] Transcriptomic analysis of human primary bronchial epithelial cells after chloropicrin treatment. Chem Res Toxicol. 2015 Oct 19;28(10):1926-35.
• [52] Neurotoxicity and underlying cellular changes of 21 mitochondrial respiratory chain inhibitors. Arch Toxicol. 2021 Feb;95(2):591-615. doi: 10.1007/s00204-020-02970-5. Epub 2021 Jan 29.